Sep. 18 at 3:37 PM
$CLDX The Phase 3 CSU studies for barzolvolimab are progressing, with full enrollment expected by summer 2026. This timeline suggests that Celldex is on track to potentially bring a new treatment option to market in the coming years, pending positive results and regulatory approval.
What sets barzolvolimab apart is its rapid onset of response and ability to clear lesions, which could give it a competitive edge over existing treatments like Nemluvio and Dupixent. Moreover, the drug’s potential extends beyond CSU, with analysts suggesting it could support a market opportunity of up to
$6 billion across various indications.
